Table 3.

Nonmyeloablative alemtuzumab/TBI conditioning regimens in adults with SCD.

Conditioning Regimen	GVHD Prophylaxis	N	Age (years)	Graft Source	Event-free Survival	Overall Survival	aGVHD (≥grade 2)	cGVHD (≥moderate)	Reference
Alemtuzumab 1 mg/kg Total body irradiation (300 cGy)	Sirolimus	30	17–65	MRD	87%	97%	0%	0%	[57]
		13	17–40		92%	100%	0%	0%	[58]
		17	14–39		89%	100%	0%	0%	[59]